5-methoxy-4-(2-methoxy-ethoxy)-2-nitro-benzaldehyde | 609343-55-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-methoxy-4-(2-methoxy-ethoxy)-2-nitro-benzaldehyde
• 英文别名: 5-methoxy-4-(2-methoxyethoxy)-2-nitrobenzaldehyde
• CAS: 609343-55-7
• 化学式: C₁₁H₁₃NO₆
• mdl: MFCD11536177
• 分子量: 255.227
• InChiKey: IPWJRIUISPJWTQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  90.6
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5-methoxy-4-(2-methoxy-ethoxy)-2-nitro-benzaldehyde 在 哌啶 、 potassium phosphate 、 tris(dibenzylidene)acetate 、 2-二环己膦基-2'-(N,N-二甲胺)-联苯 、 三氯氧磷 作用下， 以 甲醇 、 乙二醇二甲醚 为溶剂， 生成 (2,4-Dichloro-phenyl)-[7-methoxy-8-(2-methoxy-ethoxy)-4a,5,10,10a-tetrahydro-pyrimido[4,5-b]quinolin-4-yl]-amine
  参考文献：
  名称：

  Inhibition of Src kinase activity by 4-anilino-5,10-dihydro-pyrimido[4,5-b]quinolines

  摘要：

  4-(2,4-Dichloro-5-methoxy)anilino-5,10-dihydropyrimido[4,5-b]quinolines are potent inhibitors of Src kinase and Src cellular activity while having no effect on Fyn cellular activity. The corresponding 4-(2,4-dichloro-5-methoxy)anilino-pyrimido[4,5-b] quinolines are much less effective Src inhibitors. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00628-0
• 作为产物：
  描述：

  3-methoxy-4-(2-methoxyethoxy)benzaldehyde 在 硝酸 作用下， 以 1,2-二氯乙烷 为溶剂， 生成 5-methoxy-4-(2-methoxy-ethoxy)-2-nitro-benzaldehyde
  参考文献：
  名称：

  Inhibition of Src kinase activity by 4-anilino-5,10-dihydro-pyrimido[4,5-b]quinolines

  摘要：

  4-(2,4-Dichloro-5-methoxy)anilino-5,10-dihydropyrimido[4,5-b]quinolines are potent inhibitors of Src kinase and Src cellular activity while having no effect on Fyn cellular activity. The corresponding 4-(2,4-dichloro-5-methoxy)anilino-pyrimido[4,5-b] quinolines are much less effective Src inhibitors. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00628-0

文献信息

• CARBOXYLIC ACID ARYL AMIDES
  申请人：Dominique Romyr

  公开号：US20120184548A1

  公开（公告）日：2012-07-19

  Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer.

  描述了公式化合物及其药用盐，以及含有该化合物及其药用盐的药物组合物，以及该化合物和药物组合物用于治疗、控制或改善增生性疾病，包括癌症。
• [EN] QUINOLINE DYRK1 INHIBITORS<br/>[FR] INHIBITEURS DE QUINOLINE DYRK1
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012098070A1

  公开（公告）日：2012-07-26

  Compounds of Formula (I) and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer.
• Inhibition of Src kinase activity by 4-anilino-5,10-dihydro-pyrimido[4,5-b]quinolines
  作者：Diane H. Boschelli、Dennis Powell、Jennifer M. Golas、Frank Boschelli

  DOI：10.1016/s0960-894x(03)00628-0

  日期：2003.9

  4-(2,4-Dichloro-5-methoxy)anilino-5,10-dihydropyrimido[4,5-b]quinolines are potent inhibitors of Src kinase and Src cellular activity while having no effect on Fyn cellular activity. The corresponding 4-(2,4-dichloro-5-methoxy)anilino-pyrimido[4,5-b] quinolines are much less effective Src inhibitors. (C) 2003 Elsevier Ltd. All rights reserved.